Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Calcineurin inhibitors in bronchiolitis obliterans syndrome following stem cell transplantation
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 2832659
Author(s) Hostettler, Katrin E; Halter, Jörg P; Gerull, Sabine; Lardinois, Didier; Savic, Spasenija; Roth, Michael; Tamm, Michael
Author(s) at UniBasel Tamm, Michael
Roth-Chiarello, Michael
Year 2014
Title Calcineurin inhibitors in bronchiolitis obliterans syndrome following stem cell transplantation
Journal The European respiratory journal
Volume 43
Number 1
Pages / Article-Number 221-32
Abstract Bronchiolitis obliterans (BO) is a complication after allogeneic hematopoietic stem cell transplantation (HSCT). BO-management comprises intensive immunosuppression, but treatment response is poor. We investigated the effect of cyclosporine A (CsA), tacrolimus (FK506), methylprednisolone (mPRED), mycophenolate mofetil (MMF), and everolimus on the proliferation of primary lung myofibroblasts from HSCT-patients with bronchiolitis obliterans syndrome (BOS).Methods: Cells were isolated from surgical lung biopsies of 8 HSCT-patients with BOS. Proliferation was assessed by [3H]-thymidine-incorporation.Results: Biopsies revealed constrictive BO in 3 and lymphocytic bronchiolitis (LB) in 5 patients. CsA and FK506 significantly induced proliferation of myofibroblasts. mPRED and MMF caused a significant inhibition of proliferation, whereas everolimus had no effect. Co-stimulation with FK506, mPRED and MMF significantly inhibited proliferation. Serial pulmonary function tests over 12 months after lung biopsy and under the triple-therapy demonstrated that patients with LB had a significant improvement of their FEV1, whereas FEV1 of patients with BO was unchanged.Conclusion: Our data demonstrate a pro-poliferative effect of calcineurin inhibitors on primary human lung myofibroblasts obtained from patients with BOS after HSCT. In contrast, based on the observed anti-proliferative capacity of MMF in vitro, MMF-based calcineurin inhibitor-free treatment strategies should be further evaluated in patients with BO after HSCT.
Publisher Munksgaard
ISSN/ISBN 0903-1936
edoc-URL http://edoc.unibas.ch/dok/A6338067
Full Text on edoc No
Digital Object Identifier DOI 10.1183/09031936.00199312
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/23645405
ISI-Number WOS:000329552200028
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.323 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
12/05/2024